Literature DB >> 8199206

Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated.

T A Liapikos1, S Antonopoulou, S P Karabina, D C Tsoukatos, C A Demopoulos, A D Tselepis.   

Abstract

A PAF aggregating activity corresponding to 427 +/- 91, 668 +/- 111 and 1319 +/- 217 pg/mg protein was detected when LDL was preincubated at pH 3.5 or with 4 mM PMSF or both for 30 min (treatments that inactivate PAF-AH) and then oxidized with 20 microM Cu2+ at 37 degrees C for 24 h. This molecule was characterized as PAF by its chromatographic behavior on TLC and other established methods and was further characterized as 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16: PAF) by its retention time on reverse phase HPLC and by fast atom bombardment-mass spectroscopy. Native LDL incubated under non oxidizing conditions, even when PAF-AH has been inactivated, or oxidized in the absence of PAF-AH inactivating agents or after pretreatment with 0.5 mM pBPB, does not produce detectable amounts of PAF. The kinetics of PAF formation in relation to PAF-AH activity, show that the apparent rate of PAF formation as well as its total amount depends on both the existence of oxidative conditions and the remaining PAF-AH activity the first hours following the onset of oxidation. Peroxidation of the phosphatidylcholine (PC) content of native LDL produces PAF-like aggregating activity much lower than that produced when intact LDL is oxidized and is not inhibited by BN 52021 as effectively as PAF produced by LDL peroxidation. Our results provide evidence that C16: PAF is formed during LDL peroxidation when PAF-AH has been inactivated and it does not result as a product of peroxidation of the LDL-PC content.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199206     DOI: 10.1016/0005-2760(94)90210-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.

Authors:  Konstantinos P Markakis; Maria K Koropouli; Stavroula Grammenou-Savvoglou; Ewoud C van Winden; Andromaxi A Dimitriou; Constantinos A Demopoulos; Alexandros D Tselepis; Eleni E Kotsifaki
Journal:  J Lipid Res       Date:  2010-03-23       Impact factor: 5.922

2.  Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.

Authors:  D C Tsoukatos; T A Liapikos; A D Tselepis; M J Chapman; E Ninio
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

3.  Involvement of phospholipids in apolipoprotein B modification during low density lipoprotein oxidation.

Authors:  A I Karakatsani; T A Liapikos; A N Troganis; D C Tsoukatos
Journal:  Lipids       Date:  1998-12       Impact factor: 1.880

4.  Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.

Authors:  Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos
Journal:  J Lipid Res       Date:  2010-07-12       Impact factor: 5.922

5.  The relation of diet with PAF and its metabolic enzymes in healthy volunteers.

Authors:  P Detopoulou; E Fragopoulou; T Nomikos; M Yannakoulia; G Stamatakis; D B Panagiotakos; S Antonopoulou
Journal:  Eur J Nutr       Date:  2014-03-18       Impact factor: 5.614

6.  Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids.

Authors:  A Tokumura; M Toujima; Y Yoshioka; K Fukuzawa
Journal:  Lipids       Date:  1996-12       Impact factor: 1.880

Review 7.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

8.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

9.  Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis.

Authors:  Haralabos C Karantonis; Georgios Gribilas; Ioannis Stamoulis; Constantinos Giaginis; Chara Spiliopoulou; Gregorios Kouraklis; Constantinos Demopoulos; Stamatios E Theocharis
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

10.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Demosthenis B Panagiotakos; Christos Pitsavos; Christodoulos Stefanadis; Smaragdi Antonopoulou
Journal:  Lipids Health Dis       Date:  2009-06-05       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.